Updates on the Management of Patients With Lymphomas During the COVID-19 Pandemic

Updates on the Management of Patients With Lymphomas During the COVID-19 Pandemic

Thursday, September 30, 2021
Webinar -- 7:00 PM ET
https://www.clinicaloptions.com/CLLcovid2021Join1

Agenda

  • Latest Data on COVID-19 Vaccination Efficacy and Safety in Patients With Lymphomas – John Allan, MD
  • Clinical Implications of COVID-19 on Treatment Selection and Care –  Sandra E. Kurtin, PhD, ANP-C, AOCN
  • Panel Discussion, Audience Question and Answer Session

Faculty

Faculty
John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Faculty
Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Goal Statement
The goal of this activity is to provide a comprehensive, agile, and highly accessible educational curriculum designed to improve oncology healthcare professionals’ competence in providing effective personalized care for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic.

Target Audience
This educational program is intended for hematologists, oncologists, nurses, pharmacists, and advanced practitioners in hematology/oncology who care for patients with MCL, MZL, CLL/SLL, or WM receiving targeted therapeutics as part of in-home care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Provide appropriate management strategies for patients with MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies during the COVID-19 pandemic
  • Select or modify treatment based on the available clinical data, guidelines, and expert recommendations to reduce office visits and maintain efficacy
  • Integrate telemedicine for routine follow-up visits, as appropriate
  • Manage adverse events associated with treatment approaches for MCL, MZL, CLL/SLL, and WM receiving in-home care with targeted therapies or immunotherapies to ensure treatment compliance as well as improved clinical outcomes and quality of life
  • Provide counsel to patients and caregivers based on best practices for infection control

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-144-H01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.